Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| Data observationNCT05247502 | University Hospital, Clermont-FerrandPhase unknown | TERMINATED due to a lack of funding and human resources to carry out data collection | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| Other chemotherapy in association with TrastuzumabNCT01613482 | Centre Oscar LambretPHASE3 | TERMINATED Lack of enrollment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| TrastuzumabNCT01613482 | Centre Oscar LambretPHASE3 | TERMINATED Lack of enrollment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| NivolumabNCT03585465 | Centre Oscar LambretPHASE1, PHASE2 | TERMINATED Analysis conducted on spring 2025, according to the provisional schedule: the results were sufficient to conclude about all endpoints, and the sponsor defined a new end of trial on 27 Dec 2025 (modification approved on CTIS on May 26, 2026). | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| CapecitabineNCT03585465 | Centre Oscar LambretPHASE1, PHASE2 | TERMINATED Analysis conducted on spring 2025, according to the provisional schedule: the results were sufficient to conclude about all endpoints, and the sponsor defined a new end of trial on 27 Dec 2025 (modification approved on CTIS on May 26, 2026). | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| CyclophosphamideNCT03585465 | Centre Oscar LambretPHASE1, PHASE2 | TERMINATED Analysis conducted on spring 2025, according to the provisional schedule: the results were sufficient to conclude about all endpoints, and the sponsor defined a new end of trial on 27 Dec 2025 (modification approved on CTIS on May 26, 2026). | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| VinblastineNCT03585465 | Centre Oscar LambretPHASE1, PHASE2 | TERMINATED Analysis conducted on spring 2025, according to the provisional schedule: the results were sufficient to conclude about all endpoints, and the sponsor defined a new end of trial on 27 Dec 2025 (modification approved on CTIS on May 26, 2026). | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| MTR-601NCT06830642 | Motric BioPHASE2 | TERMINATED Pending further safety evaluation | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| PembrolizumabNCT04738487 | Merck Sharp & Dohme LLCPHASE3 | TERMINATED Business Reasons | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| Pembrolizumab/VibostolimabNCT04738487 | Merck Sharp & Dohme LLCPHASE3 | TERMINATED Business Reasons | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| 1ml of triamcinolone (40mg/1ml)NCT04253457 | University Hospital Plymouth NHS TrustPHASE3 | TERMINATED Standard of Care change impacted recruitment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| GSK4527226NCT06079190 | GlaxoSmithKlinePHASE2 | TERMINATED The study was terminated early due to meeting pre-specified efficacy futility criteria at planned interim analysis. | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| Monovisc 88 MG Per 4 ML Prefilled SyringeNCT05492851 | Ohio State UniversityPHASE4 | TERMINATED The study has only enrolled 6 subjects in 6 months since study initiation. Potential participants are unwilling to participate in the study due to the randomziation and blinding. Both aspects are needed to ensure a robust comparison between groups. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| Synvisc-One 48 MG in 6 ML Prefilled SyringeNCT05492851 | Ohio State UniversityPHASE4 | TERMINATED The study has only enrolled 6 subjects in 6 months since study initiation. Potential participants are unwilling to participate in the study due to the randomziation and blinding. Both aspects are needed to ensure a robust comparison between groups. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| ZilrettaNCT05492851 | Ohio State UniversityPHASE4 | TERMINATED The study has only enrolled 6 subjects in 6 months since study initiation. Potential participants are unwilling to participate in the study due to the randomziation and blinding. Both aspects are needed to ensure a robust comparison between groups. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| CisplatinNCT00421096 | Centre Oscar LambretPHASE2 | TERMINATED Problems of recruitment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| GemcitabineNCT00421096 | Centre Oscar LambretPHASE2 | TERMINATED Problems of recruitment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| Dose Level 3NCT07297160 | Baylor College of MedicinePHASE1 | WITHDRAWN The study was revised into two separate protocols to separate treatments. We will submit as separate studies. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-16 |
| Dose Level 2NCT07297160 | Baylor College of MedicinePHASE1 | WITHDRAWN The study was revised into two separate protocols to separate treatments. We will submit as separate studies. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-16 |
| Dose Level 1 (starting dose level)NCT07297160 | Baylor College of MedicinePHASE1 | WITHDRAWN The study was revised into two separate protocols to separate treatments. We will submit as separate studies. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-16 |
| Dose Level -1NCT07297160 | Baylor College of MedicinePHASE1 | WITHDRAWN The study was revised into two separate protocols to separate treatments. We will submit as separate studies. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-16 |
| PfSPZ VaccineNCT05652504 | National Institute of Allergy and Infectious Diseases (NIAID)PHASE1 | WITHDRAWN Sponsor discontinued development of the investigational vaccine for this protocol and shifted to an alternative investigational product. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-16 |
| RomidepsinNCT01947140 | Jennifer AmengualPHASE1, PHASE2 | TERMINATED Lack of funding and recruitment complications caused by COVID-19 | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-16 |
| PralatrexateNCT01947140 | Jennifer AmengualPHASE1, PHASE2 | TERMINATED Lack of funding and recruitment complications caused by COVID-19 | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-16 |
| RVU120NCT06268574 | Ryvu Therapeutics SAPHASE2 | TERMINATED Sponsor decision | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-16 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |